Sareum is a clinical stage small molecule drug development company developing next generation kinase inhibitors for autoimmune disease and cancer.
Find out more about us
24 November 2022
21 November 2022
08 November 2022
Find out more
TYK2/JAK1 inhibitor SDC-1801, targeting autoimmune diseases, is being prepared for first clinical studies
Sareum's innovative pipeline is focused on the TYK/JAK cell signalling family.
IMC SDC-1801 CTA submission, Aug 2022BioTrinity, April 2022 IMC Half Year Results, Feb 2022IMC Full Year Results, Oct 2021
Share price dataRegulatory News Service (RNS)
Sareum LimitedUnit 2A, Langford ArchLondon Road, PampisfordCambridge CB22 3FXUnited Kingdom
tel: +44 (0) 1223 497700fax: +44 (0) 1223 497701
Full-year Results 2022 ¦
Annual Report 2022 ¦